Alzheimer’s disease drug development pipeline: 2021

Cummings, Jeffrey, Lee, Garam, Zhong, Kate, Fonseca, Jorge, Taghva, Kazem·2021·Alzheimer's & Dementia: Translational Research & Clinical Interventions
DOI 10.1002/trc2.12179

Cited by (535)

Items 201–300 of 535

  1. Cyanobiphenyls: Novel H3 receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer’s disease
    Justyna Godyń, Paula Zaręba, Dorota Łażewska, Dorota Stary, David Reiner‐Link, Annika Frank, Gniewomir Latacz, Szczepan Mogilski, Maria Kaleta, Agata Doroż-Płonka et al. · 2021 · Bioorganic Chemistry
  2. Genuine selective caspase-2 inhibition with new irreversible small peptidomimetics
    Elodie Bosc, Julie Anastasie, Feryel Soualmia, Pascale Coric, Ju Youn Kim, Lily Q. Wang, Gullen Lacin, Kaitao Zhao, Ronak Patel, Eric Duplus et al. · 2022 · Cell Death and Disease
  3. Research attitudes in families of individuals with Down syndrome: importance for clinical trials
    Ira T. Lott, Katharine A. Kirby, Eric W. Doran, Joshua D. Grill · 2022 · Alzheimer s Research & Therapy
  4. Preclinical trials in Alzheimer’s disease: Sample size and effect size for behavioural and neuropathological outcomes in 5xFAD mice
    Mahvish Faisal, Jana Aid, Nodirov Bekzod Holiqjon o‘g‘li, Benjamin Lee, Miriam Ann Hickey · 2023 · PLoS ONE
  5. Nanotechnology‐empowered therapeutics targeting neurodegenerative diseases
    Zhiren Wang, Karina Marie Gonzalez, Leyla Estrella Cordova, Jianqin Lu · 2023 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
  6. Development of novel salicylic acid–donepezil–rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease
    Yi Ming Zhou, Ying He, Xue Teng, Jing Mi, Jing Yang, Rongrui Wei, Wenmin Liu, Qinge Ma, Zhenghuai Tan, Zhipei Sang · 2023 · Journal of Enzyme Inhibition and Medicinal Chemistry
  7. Antioxidants in anti‐Alzheimer's disease drug discovery
    Jianan Guo, Yalan Zhu, Jia Zhi, Qiuwen Lou, Renren Bai, Yiling He · 2025 · Ageing Research Reviews
  8. Development and Biological Characterization of a Novel Selective TrkA Agonist with Neuroprotective Properties against Amyloid Toxicity
    Thanasis Rogdakis, Despoina Charou, Alessia Latorrata, Eleni Papadimitriou, Alexandros Tsengenes, Christina Athanasiou, Maria Anna Papadopoulou, Constantina Chalikiopoulou, Θεοδώρα Κάτσιλα, Isbaal Ramos et al. · 2022 · Biomedicines
  9. The Role of Immunity in Alzheimer's Disease
    Róisín M. McManus · 2022 · Advanced Biology
  10. Amyloid-β Induces Cdh1-Mediated Rock2 Stabilization Causing Neurodegeneration
    Rebeca Lapresa, Jesús Agulla, Sonia González-Guerrero, Juan Pedro Bolaños, Ángeles Almeida · 2022 · Frontiers in Pharmacology
  11. Evolution of Alzheimer's disease research from a health-tech perspective: Insights from text mining
    Dominic D. Martinelli · 2022 · International Journal of Information Management Data Insights
  12. Light-based gamma entrainment with novel invisible spectral flicker stimuli
    Luna Skytte Hansen, Marcus Schultz Carstensen, Mark Alexander Henney, N. Mai Nguyen, Martin William Thorning‐Schmidt, Jes Broeng, Paul Michael Petersen, T Andersen · 2024 · Scientific Reports
  13. Machine learning in early diagnosis of neurological diseases: Advancing accuracy and overcoming challenges
    Yuru Li, Xiaowei Chang, Jianlin Wu, Yu‐Chen Liu, Hailu Wang, Yiyin Zhang · 2025 · Brain Network Disorders
  14. Experimental modelling of Alzheimer's disease for therapeutic screening
    Laura Blaikie, Graeme Kay, Patrı́cia Maciel, Paul Kong Thoo Lin · 2022 · European Journal of Medicinal Chemistry Reports
  15. Amyloid precursor protein and presenilin‐1 knock‐in immunodeficient mice exhibit intraneuronal Aβ pathology, microgliosis, and extensive neuronal loss
    Pravin Yeapuri, Jatin Machhi, Emma G. Foster, Rana Kadry, Shaurav Bhattarai, Yaman Lu, Susmita Sil, Roshan Sapkota, Shefali Srivastava, Mohit Kumar et al. · 2025 · Alzheimer s & Dementia
  16. Is Aducanumab for LMICs? Promises and Challenges
    Illangage P. C. Gunawardena, Thaarvena Retinasamy, Mohd. Farooq Shaikh · 2021 · Brain Sciences
  17. ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease – Study Protocol and Baseline Characteristics
    Anniina Snellman, Laura L. Ekblad, Mikko Koivumäki, Noora Lindgrén, Jouni Tuisku, Merja Perälä, Lila Kallio, Riina Lehtonen, Virva Saunavaara, Jani P. Saunavaara et al. · 2022 · Frontiers in Neurology
  18. Lipidopathy disrupts peripheral and central amyloid clearance in Alzheimer's disease: Where are our knowledge
    Shahram Darabi, Enam Alhagh Charkhat Gorgich, Fatemeh Moradi, Auob Rustamzadeh · 2025 · IBRO Neuroscience Reports
  19. Emerging Molecular Targets in Neurodegenerative Disorders: New Avenues for Therapeutic Intervention
    Ezgı Eroglu, Nuşin HARMANCI · 2025 · Basic & Clinical Pharmacology & Toxicology
  20. Missing lnc(RNAs) in Alzheimer’s Disease?
    Rafaela Policarpo, Constantin van Outryve d’Ydewalle · 2021 · Genes
  21. Social connectedness and cognitive decline
    Adam R. Roth · 2022 · The Lancet Healthy Longevity
  22. Projections of costs and quality adjusted life years lost due to dementia from 2020 to 2050: A population‐based microsimulation study
    Chiara C. Brück, Frank J. Wolters, M. Arfan Ikram, Inge M.C.M. de Kok · 2023 · Alzheimer s & Dementia
  23. Failure, Success, and Future Direction of Alzheimer Drugs Targeting Amyloid‐β Cascade: Pros and Cons of Chemical and Biological Modalities
    Jimin Kim, Hanna Jeon, Hye Yun Kim, Young Soo Kim · 2023 · ChemBioChem
  24. Targeting the molecular web of Alzheimer’s disease: unveiling pathways for effective pharmacotherapy
    Devika Jadhav, Nikita Saraswat, Neeraj S. Vyawahare, Devendra Shriram Shirode · 2024 · The Egyptian Journal of Neurology Psychiatry and Neurosurgery
  25. Design, synthesis and anti-TNBC activity of Azeliragon triazole analogues
    Jizhao Xie, Huanji Xu, Xinduo Wu, Yunfeng Xie, Xiuhong Lu, Lisheng Wang · 2021 · Bioorganic & Medicinal Chemistry Letters
  26. Identification of a Thyroid Hormone Derivative as a Pleiotropic Agent for the Treatment of Alzheimer’s Disease
    Massimiliano Runfola, Michele Perni, Xiaoting Yang, Maria Marchese, Andrea Bacci, Serena Mero, Filippo Maria Santorelli, Beatrice Polini, Grazia Chiellini, Daniela Giuliani et al. · 2021 · Pharmaceuticals
  27. Lion’s Mane (Hericium erinaceus) Exerts Anxiolytic Effects in the rTg4510 Tau Mouse Model
    Mya N. Rodriguez, Stephen L. P. Lippi · 2022 · Behavioral Sciences
  28. Nasal nanotherapeutics for central nervous system disorders: Bridging the translational gap in central nervous system drug delivery
    Yi-Bing Zhang, Mohan Liu, Yusi Wang, Die Hu, Siwen Wu, Binyan Zhao, Bailing Zhou, Li Yang · 2025 · European Journal of Pharmacology
  29. Rational design and synthesis of modified natural peptides from Boana pulchella (anura) as acetylcholinesterase inhibitors and antioxidants
    Ivan Sanchís, Roque Spinelli, Nicolás A. Aschemacher, Álvaro Siano · 2021 · Amino Acids
  30. Vesicular dysfunction and pathways to neurodegeneration
    Patrick Alfryn Lewis · 2021 · Essays in Biochemistry
  31. ADSS: A Composite Score to Detect Disease Progression in Alzheimer’s Disease
    Guogen Shan, Xinlin Lu, Zhigang Li, Jessica Caldwell, Charles B. Bernick, Jeffrey L. Cummings · 2024 · Journal of Alzheimer s Disease Reports
  32. Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer’s Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study
    Julie Chandler, Wenyu Ye, Xiaojuan Mi, Erin Gautier Doty, Joseph A. Johnston · 2024 · Journal of Alzheimer s Disease
  33. In-vivo neuronal dysfunction by Aβ and tau overlaps with brain-wide inflammatory mechanisms in Alzheimer’s disease
    Lazaro M. Sanchez-Rodriguez, Ahmed Faraz Khan, Quadri Adewale, Gleb Bezgin, Joseph Therriault, Jaime Fernández Arias, Stijn Servaes, Nesrine Rahmouni, Cécile Tissot, Jenna Stevenson et al. · 2024 · Frontiers in Aging Neuroscience
  34. On the Clinimetrics of the Montreal Cognitive Assessment: Cutoff Analysis in Patients with Mild Cognitive Impairment due to Alzheimer’s Disease
    Ciro Rosario Ilardi, Alina Menichelli, Marco Michelutti, Tatiana Cattaruzza, Giovanni Federico, Marco Salvatore, Alessandro Iavarone, Paolo Manganotti · 2024 · Journal of Alzheimer s Disease
  35. Human iPSC-Derived Neurons as A Platform for Deciphering the Mechanisms behind Brain Aging
    Chuan‐Chuan Chao, Po-Wen Shen, Tsai‐Yu Tzeng, Hsing‐Jien Kung, Ting‐Fen Tsai, Yu‐Hui Wong · 2021 · Biomedicines
  36. Endo-Lysosomal and Autophagy Pathway and Ubiquitin-Proteasome System in Mood Disorders: A Review Article
    Petala Matutino Santos, Giovanna Pereira Campos, Camila Fernandes Nascimento · 2023 · Neuropsychiatric Disease and Treatment
  37. A 12-month randomised pilot trial of the Alzheimer’s and music therapy study: a feasibility assessment of music therapy and physical activity in patients with mild-to-moderate Alzheimer’s disease
    Anna Maria Matziorinis, Birthe Kristin Flo, Stavros Skouras, Kathrine Dahle, Anne Henriksen, F. Hausmann, Tobba Therkildsen Sudmann, Christian Gold, Stefan Koelsch · 2023 · Pilot and Feasibility Studies
  38. Oligosaccharides from black ginseng innovatively prepared by low‐temperature steam‐heating process ameliorate cognitive impairment in Alzheimer's disease mice via the Keap‐1/Nrf2 pathway
    Weiyin Xu, Peng Yu, Simeng Shao, Zhaoyang Xie, Yi Wu, Jianing Liu, Tianyang Xu, Guangzhi Cai, Hongmei Yang · 2024 · Journal of the Science of Food and Agriculture
  39. A phase I trial of accelerated intermittent theta burst rTMS for amnestic MCI
    Aghamoosa, Stephanie, Lopez, James, Rbeiz, Katrina, Fleischmann, Holly H, Horn, Olivia, Madden, Katrina, Caulfield, Kevin A, Antonucci, Michael U, Revuelta, Gonzalo, McTeague, Lisa M et al. · 2024 · Journal of Neurology, Neurosurgery & Psychiatry
  40. Potential role of blood pressure variability and plasma neurofilament light in the mechanism of comorbidity between Alzheimer's disease and cerebral small vessel disease
    Qin Li, Shu Su, Yuxue Feng, Meng Jia, Jiehong Zhan, Zixuan Liao, Jiayu Li, Xiaofeng Li, Alzheimer’s Disease Neuroimaging Initiative · 2024 · Alzheimer s & Dementia
  41. Human serum albumin-3-amino-1-propanesulfonic acid conjugate inhibits amyloid-β aggregation and mitigates cognitive decline in Alzheimer's disease
    Divya Shastri, Chaitany Jayprakash Raorane, Vinit Raj, Sang-Kil Lee · 2025 · Journal of Controlled Release
  42. Alzheimer’s Disease and Toxins Produced by Marine Dinoflagellates: An Issue to Explore
    Maria João Botelho, Jelena Milinović, Narcisa Maria Bandarra, Carlos Vale · 2022 · Marine Drugs
  43. Impact of Donepezil on Brain Glucose Metabolism Assessed Using [18F]2-Fluoro-2-deoxy-D-Glucose Positron Emission Tomography Imaging in a Mouse Model of Alzheimer’s Disease Induced by Intracerebroventricular Injection of Amyloid-Beta Peptide
    Gaëlle Hugon, Sébastien Goutal, Marie Sarazin, Michel Bottlaender, Fabien Caillé, Marine Droguerre, Mathieu Charvériat, Alexandra Winkeler, Nicolas Tournier · 2022 · Frontiers in Neuroscience
  44. Vitamin K: a Potential Neuroprotective Agent
    Kaberi Chatterjee, Papiya Mitra Mazumder, Sugato Banerjee · 2023 · Revista Brasileira de Farmacognosia
  45. Beyond the classical amyloid hypothesis in Alzheimer's disease: Molecular insights into current concepts of pathogenesis, therapeutic targets, and study models
    Atsadang Theerasri, Sakawrat Janpaijit, Tewin Tencomnao, Anchalee Prasansuklab · 2022 · WIREs Mechanisms of Disease
  46. RNA-based therapies for neurodegenerative disease: Targeting molecular mechanisms for disease modification
    Vishal Bhati, Sonima Prasad, Atul Kabra · 2025 · Molecular and Cellular Neuroscience
  47. Engineering exosomes for Alzheimer's disease: Multi‐target therapeutic strategies from pathogenesis to clinical translation
    Y C Zhang, Zhenyang Li, Haien Guan, Zhenhua Qiu, Chunlin Zou · 2025 · Clinical and Translational Medicine
  48. Potent therapeutic targets for treatment of Alzheimer's disease: Amyloid degrading enzymes
    Hang Choi, Eungchan Kim, J. Choi, E. Park, Hyuck Jin Lee · 2021 · Bulletin of the Korean Chemical Society
  49. 4-Hydroxycinnamic acid attenuates neuronal cell death by inducing expression of plasma membrane redox enzymes and improving mitochondrial functions
    Sujin Park, Yoon A Kim, Jaewang Lee, Hyunsoo Seo, Sang‐Jip Nam, Dong‐Gyu Jo, Dong‐Hoon Hyun · 2022 · Food Science and Human Wellness
  50. Real-World Use of Symptomatic Treatments in Early Alzheimer’s Disease
    Maria João Garcia, Regina M. Leadley, Shona Lang, Janine Ross, Elizabeth Vinand, Clive G. Ballard, Sandro Gsteiger · 2022 · Journal of Alzheimer s Disease
  51. Applications of Nanoparticles in Alzheimer’s Disease
    Yiming Liu, Yong Shen · 2023 · Journal of Alzheimer s Disease
  52. Exploring Plausible Therapeutic Targets for Alzheimer's Disease using Multi-omics Approach, Machine Learning and Docking
    S. Akila Parvathy Dharshini, Nela Pragathi Sneha, Dhanusha Yesudhas, Arulsamy Kulandaisamy, Uday Rangaswamy, Shanmugam Anusuya, Y‐h. Taguchi, M. Michael Gromiha · 2022 · Current Topics in Medicinal Chemistry
  53. Neuroprotective Epigenetic Changes Induced by Maternal Treatment with an Inhibitor of Soluble Epoxide Hydrolase Prevents Early Alzheimer′s Disease Neurodegeneration
    Clara Bartra, Alba Irisarri, Ainhoa Villoslada, Rubén Corpas, Samuel Aguirre, Elisa García-Lara, Cristina E. Sunol, Mercè Pallàs, Christian Griñán‐Ferré, Coral Sanfeliu · 2022 · International Journal of Molecular Sciences
  54. Stealth Liposomes Encapsulating a Potent ACAT1/SOAT1 Inhibitor F12511: Pharmacokinetic, Biodistribution, and Toxicity Studies in Wild-Type Mice and Efficacy Studies in Triple Transgenic Alzheimer’s Disease Mice
    Adrianna L. De La Torre, Thao Nguyen Thanh Huynh, Catherine C.Y. Chang, Darcy B. Pooler, Dylan B. Ness, Lionel D. Lewis, Sanjana Pannem, Yichen Feng, Kimberley S. Samkoe, William F. Hickey et al. · 2023 · International Journal of Molecular Sciences
  55. Facile method to incorporate high-affinity ACAT/SOAT1 inhibitor F12511 into stealth liposome-based nanoparticle and demonstration of its efficacy in blocking cholesteryl ester biosynthesis without overt toxicity in neuronal cell culture
    Adrianna L. De La Torre, Caleb Smith, Joseph Granger, Faith L. Anderson, Taylor C. Harned, Matthew C. Havrda, Catherine C.Y. Chang, Ta‐Yuan Chang · 2021 · Journal of Neuroscience Methods
  56. An Argument for Simple Tests of Treatment of Alzheimer’s Disease
    Timothy P Daly, Ignacio Mastroleo, Vincent Henry, Mathieu Bourdenx · 2022 · Journal of Alzheimer s Disease
  57. Tau immunotherapy in Alzheimer’s disease and progressive supranuclear palsy
    Nastaran Karimi, Feyza Bayram Catak, Ebru Ozturk Arslan, Amene Saghazadeh, Nima Rezaei · 2022 · International Immunopharmacology
  58. Innovations in Alzheimer’s disease diagnostic technologies: clinical prospects of novel biomarkers, multimodal integration, and non-invasive detection
    Rui Wang, Siqin Peng, Jianrong Zhu, Ye Xu, Minghao Wang, Ling Zhang, Yilan Qiu, Defu Hou, Qinglin Wang, Rushi Liu · 2025 · Frontiers in Neurology
  59. Aerial part of Houttuynia cordata reverses memory impairment by regulating amyloid beta accumulation and neuroinflammation in Alzheimer's disease model
    In Gyoung Ju, Seungmin Lee, Jin Gyu Choi, Namkwon Kim, Eugene Huh, Jong Kil Lee, Myung Sook Oh · 2023 · Phytotherapy Research
  60. Nanocarrier-mediated curcumin delivery: An adjuvant strategy for CNS disease treatment
    Sandip Godse, Lina Zhou, Swarna Sakshi, Bhupesh Singla, Udai Pratap Singh, Santosh Kumar · 2023 · Experimental Biology and Medicine
  61. Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer’s disease
    Linus Jönsson, Milana Ivkovic, Alireza Atri, Ron L. H. Handels, Anders Gustavsson, Julie Hviid Hahn‐Pedersen, Teresa León, Mathias Lilja, Jens Gundgaard, Lars Lau Rakêt · 2024 · Alzheimer s Research & Therapy
  62. Neuroprotective efficiency of celecoxib vesicular bilosomes for the management of lipopolysaccharide-induced Alzheimer in mice employing 23 full factorial design
    Asmaa Badawy Darwish, Abeer Salama, Mostafa Mohamed Younis · 2024 · Inflammopharmacology
  63. Promising Natural Remedies for Alzheimer’s Disease Therapy
    Amin Mahmood Thawabteh, Aseel Wasel Ghanem, Sara AbuMadi, Dania Thaher, Weam Jaghama, Donia Karaman, Rafik Karaman · 2025 · Molecules
  64. Targeting of phosphorylated tau at threonine 181 by a Qβ virus‐like particle vaccine is safe, highly immunogenic, and reduces disease severity in mice and rhesus macaques
    Nicole M. Maphis, Jonathan P. Hulse, Julianne Peabody, Somayeh Dadras, Madelin J. Whelpley, Manas Kandath, Colin M. Wilson, Sasha Hobson, Jeff Thompson, Suttinee Poolsup et al. · 2025 · Alzheimer s & Dementia
  65. Rationally Designed Bicyclic Peptides Prevent the Conversion of Aβ42 Assemblies Into Fibrillar Structures
    Tatsuya Ikenoue, Francesco A. Aprile, Pietro Sormanni, Michele Vendruscolo · 2021 · Frontiers in Neuroscience
  66. Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats
    Benoît Souchet, Mickaël Audrain, Yuchen Gu, Mattias F. Lindberg, Nicola Salvatore Orefice, Emilie Rey, Nathalie Cartier, Nathalie Janel, Laurent Meijer, Jérôme Braudeau · 2022 · The Journal of Prevention of Alzheimer s Disease
  67. Biophysical characterization as a tool to predict amyloidogenic and toxic properties of amyloid‐β42 peptides
    Adeola Shobo, Alexander Röntgen, Mark A. Hancock, Gerd Multhaup · 2022 · FEBS Letters
  68. Advances in Recapitulating Alzheimer’s Disease Phenotypes Using Human Induced Pluripotent Stem Cell-Based In Vitro Models
    Md Fayad Hasan, Eugenia V. Trushina · 2022 · Brain Sciences
  69. Elucidation of Pharmacological Mechanism Underlying the Anti-Alzheimer’s Disease Effects of Evodia rutaecarpa and Discovery of Novel Lead Molecules: An In Silico Study
    Lulu Zhang, Jia Xu, Jiejie Guo, Yun Wang, Qinwen Wang · 2023 · Molecules
  70. Study on the effect of 40 Hz non-invasive light therapy system. A protocol for a randomized, double-blinded, placebo-controlled clinical trial
    Mikkel Pejstrup Agger, Maibritt Horning, Marcus Schultz Carstensen, Else Rubæk Danielsen, Anders Ohlhues Baandrup, Mai Nguyen, Peter Høgh, Kamilla Woznica Miskowiak, Paul Michael Petersen, Kristoffer Hougaard Madsen et al. · 2023 · Frontiers in Aging Neuroscience
  71. Identification of diagnostic molecules and potential traditional Chinese medicine components for Alzheimer’s disease by single cell RNA sequencing combined with a systematic framework for network pharmacology
    Tao Wang, Xinlei Zhang, Wenxin Liu, Fangli Ning, Xingling Hu, Lei Qin, Mengmeng Cui, Jinyue Yang, Shi Lv, Qian Wang · 2024 · Frontiers in Medicine
  72. New plasma LC-MS/MS assays for the quantitation of beta-amyloid peptides and identification of apolipoprotein E proteoforms for Alzheimer’s disease risk assessment
    Darren M. Weber, Jueun C Kim, Scott M. Goldman, Nigel J. Clarke, Michael K. Racke · 2024 · Journal of Investigative Medicine
  73. Navigating the future of Alzheimer’s care in Ireland - a service model for disease-modifying therapies in small and medium-sized healthcare systems
    Iracema Leroi, Helena Dolphin, Rachel Dinh, Tony Foley, Seán Kennelly, Irina Kinchin, Rónán Ó’Caoimh, Seán O’Dowd, Laura O’Philbin, Susan O’Reilly et al. · 2024 · BMC Health Services Research
  74. Gene therapy in Aβ-induced cell and mouse models of Alzheimer’s disease through compensating defective mitochondrial complex I function
    Hongzhi Li, Zhuo Chen, Yuqi Shen, Ting Xiong, Andong Chen, Lixia Chen, Yifan Ye, Qingyou Jiang, Yaxi Zhang, Junlong Sun et al. · 2024 · Journal of Translational Medicine
  75. Brain Stimulation in Alzheimer’s Disease Trials
    Alberto Benussi, Barbara Borroni · 2024 · Journal of Alzheimer s Disease
  76. A meta-analysis of the efficacy of physical exercise interventions on activities of daily living in patients with Alzheimer's disease
    Yang Xiao, Yu Fan, Zhengteng Feng · 2024 · Frontiers in Public Health
  77. In vitro and in vivo Investigations of 4-Substituted 2-Phenylquinazoline derivatives as multipotent ligands for the treatment of Alzheimer’s disease
    Vijay Kumar, Kailash Jangid, Vishal Kumar, Vishal Kumar, Jayapriya Mishra, Tania Arora, Ashish Ranjan Dwivedi, Puneet Kumar, Jasvinder Singh Bhatti, Jyoti Parkash et al. · 2025 · Bioorganic Chemistry
  78. Disease modification is not all — we need symptomatic therapies for Alzheimer disease
    Jeffrey L. Cummings · 2021 · Nature Reviews Neurology
  79. Recent developments in the synthesis of pyridine analogues as a potent anti-Alzheimer's therapeutic leads
    Aluru Rammohan, Baki Vijaya Bhaskar, Grigory V. Zyryanov · 2022 · Elsevier eBooks
  80. MODELLING THE PAN-EUROPEAN ECONOMIC BURDEN OF ALZHEIMER'S DISEASE
    Rui Martins, Michael Urbich, K. Brännvall, Mattia Gianinazzi, J.E. Ching, Charles P. Khoury, Youssef Hanna El-Hayek · 2022 · Journal of Aging Research and Lifestyle
  81. Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia
    Benoît Souchet, Mickaël Audrain, Sandro Alves, Romain Roger Fol, Satoru Tada, Nicola Salvatore Orefice, Brigitte Potier, P. Dutar, Jean‐Marie Billard, Nathalie Cartier et al. · 2022 · The Journal of Prevention of Alzheimer s Disease
  82. Ursolic acid and its isomer oleanolic acid are responsible for the anti-dementia effects of Ocimum sanctum in olfactory bulbectomized mice
    Hien Thu Nguyen, Xoan Thi Le, Tai Van Nguyen · 2022 · Journal of Natural Medicines
  83. Alzheimer’s disease: a scoping review of biomarker research and development for effective disease diagnosis
    Khushboo Govind Faldu, Jigna Shah · 2022 · Expert Review of Molecular Diagnostics
  84. In vivo characterization of cerebrovascular impairment induced by amyloid β peptide overload in glymphatic clearance system using swept-source optical coherence tomography
    Yao Yu, Ning Zhang, Ben Xiang, Ning Ding, Jian Liu, Jiangmei Huang, Min Zhao, Yuqian Zhao, Yi Wang, Zhenhe Ma · 2023 · Neurophotonics
  85. Hemispheric Asymmetry and Atypical Lobar Progression of Alzheimer-Type Tauopathy
    Cécilia Tremblay, Geidy E. Serrano, Anthony J. Intorcia, Jasmine R. Curry, Lucia I. Sue, Courtney M. Nelson, Jessica E. Walker, Michael J. Glass, Richard A. Arce, Adam Fleisher et al. · 2022 · Journal of Neuropathology & Experimental Neurology
  86. Antiepileptic Drugs Modulate Alzheimer-Related Tau Aggregation in a Neuronal Activity-Independent Manner
    Yuki Ito, Shuko Takeda, Sayaka Moroi, Tsuneo Nakajima, Akane Oyama, Kunihiro Miki, Nanami Sugihara, Yoichi Takami, Yasushi Takeya, Munehisa Shimamura et al. · 2023 · Dementia and Geriatric Cognitive Disorders
  87. Integrating serum pharmacochemistry and network pharmacology to reveal the active constituents and mechanism of Corydalis Rhizoma in treating Alzheimer’s disease
    Yan Lyu, Yu Wang, Jian‐You Guo, Yuqing Wang, Yifan Lu, Zhuangzhuang Hao, Tingyue Jiang, Wenxin Fan, Yihua Li, Jinli Shi · 2023 · Frontiers in Aging Neuroscience
  88. Clinical importance in Alzheimer’s disease: effects of anchor agreement and disease severity
    Marta Stojanovic, Cynthia M. Mikula, Samantha E. John, Andrew M. Kiselica · 2024 · Aging Clinical and Experimental Research
  89. Novel multifunctional tacrine–donepezil hybrids against Alzheimer's disease: Design synthesis and bioactivity studies
    Gülşah Bayraktar, Manuela Bartolini, María Laura Bolognesi, Mümin Alper Erdoğan, Güliz Armağan, Ece Bayır, Aylin Şendemir, Donatella Bagetta, Stefano Alcaro, Vildan Alptüzün · 2024 · Archiv der Pharmazie
  90. Dissonance in the face of Alzheimer's disease breakthroughs: clinician and lay stakeholder acceptance, concerns and willingness to pay for emerging disease-modifying therapies
    Irina Kinchin, Sharon Walsh, Rachel Dinh, Margaret Kapuwa, Seán Kennelly, Ann-Marie Miller, Anne Nolan, Seán O’Dowd, Laura O’Philbin, Suzanne Timmons et al. · 2024 · The British Journal of Psychiatry
  91. Probing new 3-hydrazinyl indole phenacetamide derivatives as multitarget anti-Alzheimer: Synthesis, in vivo, in vitro, and in silico studies
    Mona F. Said, Walaa Wadie, Enas Ahmed Abd El-Haleim, Riham A. El‐Shiekh, Haidy H. El-Zoheiry · 2025 · European Journal of Medicinal Chemistry
  92. Advances in gait research related to Alzheimer’s disease
    Shuding Yan, Xiaoping Yun, Qiang Liu, Zhenmei Hong, Yufan Chen, Shuijing Zhang · 2025 · Frontiers in Neurology
  93. Relationship between Cerebrospinal Fluid Matrix Metalloproteinases Levels and Brain Amyloid Deposition in Mild Cognitive Impairment
    Yuuki Sasaki, Noriyuki Kimura, Yasuhiro Aso, Kenichi Yabuuchi, Miki Aikawa, Etsuro Matsubara · 2021 · Biomolecules
  94. N,N-dimethylacetamide targets neuroinflammation in Alzheimer’s disease in in-vitro and ex-vivo models
    Zeng-Hui Wei, Jagadish Koya, Nikita Acharekar, Jesus Trejos, Xing-Duo Dong, Francis A.X. Schanne, Charles R. Ashby, Sandra E. Reznik · 2023 · Scientific Reports
  95. Prenylated Flavanone Isolated from Dalea Species as a Potential Multitarget-Neuroprotector in an In Vitro Alzheimer’s Disease Mice Model
    María Daniela Santi, Diego Carvalho, Rosina Dapueto, Manuela Bentura, Maia Zeni, Loreto Martínez‐González, Ana Martı́nez, Mariana Andrea Peralta, Ana María Rey, Javier Giglio et al. · 2024 · Neurotoxicity Research
  96. Efficacy of preclinical pharmacological interventions against alterations of neuronal network oscillations in Alzheimer's disease: A systematic review
    Arturo G. Isla, Hugo Balleza‐Tapia, André Fisahn · 2021 · Experimental Neurology
  97. A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease
    Amir Abbas Tahami Monfared, Ali Tafazzoli, Weicheng Ye, Ameya Chavan, Kristen A. Deger, Quanwu Zhang · 2022 · Neurology and Therapy
  98. The value of maintaining cognition in patients with mild cognitive impairment: The innovation headroom and potential cost‐effectiveness of roflumilast
    Ron L. H. Handels, Sabine Elisabeth Grimm, Arjan Blokland, Nina Possemis, Inez H.G.B. Ramakers, Anke Sambeth, Frans R.J. Verhey, Stephanie J. B. Vos, Manuela A. Joore, Jos Prickaerts et al. · 2023 · Alzheimer s & Dementia
  99. The roles of natural triterpenoid saponins against Alzheimer's disease
    Jie‐Chun Zhou, Huilin Li, Yu Jerry Zhou, Xi‐Tao Li, Zhiyou Yang, Chihiro Tohda, Katsuko Komatsu, Xiu‐Hong Piao, Yue‐Wei Ge · 2023 · Phytotherapy Research
  100. Food Functional Factors in Alzheimer’s Disease Intervention: Current Research Progress
    Rongzu Nie, Huo-Min Luo, Ya-Ping Liu, Shuangshuang Wang, Yan-Jie Hou, Chen Chen, Hang Wang, Hui-Lin Lv, Xing-Yue Tao, Zhao-Hui Jing et al. · 2024 · Nutrients